BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:40:00 PM | Browse: 697 | Download: 699
 |
Received |
|
2013-09-11 09:14 |
 |
Peer-Review Started |
|
2013-09-13 15:45 |
 |
To Make the First Decision |
|
2013-09-27 17:01 |
 |
Return for Revision |
|
2013-09-29 20:12 |
 |
Revised |
|
2013-10-04 15:34 |
 |
Second Decision |
|
2013-10-17 14:51 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-10-18 08:10 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2013-11-07 21:56 |
 |
Typeset the Manuscript |
|
2013-11-27 09:48 |
 |
Publish the Manuscript Online |
|
2013-12-18 10:39 |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Review |
Article Title |
Cross-talk between the thyroid and liver: A new target for nonalcoholic fatty liver disease treatment
|
Manuscript Source |
Invited Manuscript |
All Author List |
Yue-Ye Huang, Aaron M Gusdon and Shen Qu |
Funding Agency and Grant Number |
|
Corresponding Author |
Shen Qu, Professor, Department of Endocrinology and Metabolism, Shanghai 10th People's Hospital, School of Medicine, Tongji University, No301 Middle Yanchang Road, Shanghai 200072, China. qushencn@hotmail.com |
Key Words |
Thyroid hormone; Thyroid hormone receptor; Nonalcoholic fatty liver disease; Obesity |
Core Tip |
The clinical findings that nonalcoholic fatty liver disease (NAFLD) patients have more prevalence of subclinical hypothyroidism and patients with hypothyroidism may develop fatty liver give the evidence that dyslipidemia and fatty liver have some relationship with thyroid dysfunction, and thyroid hormone and its receptor may be a therapeutic target for NAFLD. We review here that thyroid hormone and TR are a potential target for pharmacologic treatments that can benefit NAFLD patients a lot. |
Publish Date |
2013-12-18 10:39 |
Citation |
Huang YY, Gusdon AM, Qu S. Cross-talk between the thyroid and liver: A new target for nonalcoholic fatty liver disease treatment. World J Gastroenterol 2013; 19(45): 8238-8246 |
URL |
http://www.wjgnet.com/1007-9327/full/v19/i45/8238.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v19.i45.8238 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345